Clinical trial NCT04643886: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
Official title: A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Dry Age-related Macular Degeneration
Geographic Atrophy
Macular Degeneration
Retinal Disease
Retinal Degeneration
Lead sponsor: Gemini Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2020-11-25
Enrollment: 62
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Detailed description: This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.

Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment naïve subjects that did not participate in the GEM-CL-10301 Study and who meet all eligibility criteria will be enrolled.

Eligibility criteria: Inclusion Criteria:

1. At least 50 years old at the time of signed informed consent.
2. Must have one of the following genetic profiles:

   1. Genetic Profile A.
   2. Genetic Profile B.
3. BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale (approximately equivalent to Snellen VA of 20/25 to 20/320).
4. Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the study eye must be within 0.5 to 15.01- and 7- disc areas.
5. Sufficiently clear ocular media and able to cooperate with ophthalmic visual function testing and anatomic assessment in the study eye.
6. Understands the full nature and purpose of the study and provides informed consent prior to initiation of any study procedure; all subjects with a reproductive potential must agree to use effective contraceptive methods through the end of study (EOS) Visit.

Exclusion Criteria:

1. Presence of the following ocular conditions - in the study eye:

   1. Any history of exudative Age-related Macular Degeneration or choroidal neovascularization.
   2. Any active ocular disease or condition that could confound the assessment of the macula or be a contraindication to IVT injection.
   3. Any intraocular surgery, with the exception of stable intraocular lens replacement surgery more than 3 months prior to consent.
   4. Aphakia or complete absence of the posterior capsule.
   5. History of laser therapy to the macula or fundus or extensive laser to the retina.
   6. Prior corneal transplant.
2. Presence of any of the following ocular conditions - in either eye:

   1. History of herpetic infection.
   2. Concurrent disease that could require medical or surgical intervention during the study period.
   3. Active uveitis and/or vitritis (grade: trace or above).
   4. History of idiopathic or autoimmune-associated uveitis.
   5. Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or endophthalmitis.
   6. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination.
3. In the opinion of the Investigator, the subject has any prior or ongoing medical condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance or study follow-up, or confound data interpretation throughout the follow-up period.
4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during the study.
5. Current use of medications known to be toxic to the lens, retina, or optic nerve.
6. Use of any investigational new drug or other experimental treatment in the last 6 months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device implantation (other than PCIOL placement following cataract surgery)

Primary outcomes:
measure: Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events.
timeFrame: 18 months
Secondary outcomes:
measure: To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (BCVA) scores as assessed by ETDRS scale.
timeFrame: 6 months
measure: To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible.
timeFrame: 6 months
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Gemini Clinical Trial Site
state: Arizona
city: Bakersfield
country: United States
facility: Gemini Clinical Trial Site
state: California
city: Beverly Hills
country: United States
facility: Gemini Clinical Trial Site
state: California
city: Oxnard
country: United States
facility: Gemini Clinical Trial Site
state: California
city: Poway
country: United States
facility: Gemini Clinical Trial Site
state: California
city: Santa Barbara
country: United States
facility: Gemini Clinical Trial Site
state: California
city: Santa Maria
country: United States
facility: Gemini Clinical Trial Site
state: California
city: Golden
country: United States
facility: Gemini Clinical Trial Site
state: Colorado
city: New London
country: United States
facility: Gemini Clinical Trial Site
state: Connecticut
city: Palm Beach Gardens
country: United States
facility: Gemini Clinical Trial Site
state: Florida
city: Saint Petersburg
country: United States
facility: Gemini Clinical Trial Site
state: Florida
city: Tallahassee
country: United States
facility: Gemini Clinical Trial Site
state: Florida
city: Winter Haven
country: United States
facility: Gemini Clinical Trial Site
state: Florida
city: Augusta
country: United States
facility: Gemini Clinical Trial Site
state: Georgia
city: Marietta
country: United States
facility: Gemini Clinical Trial Site
state: Georgia
city: Oak Park
country: United States
facility: Gemini Clinical Trial Site
state: Illinois
city: Indianapolis
country: United States
facility: Gemini Clinical Trial Site
state: Indiana
city: Chesterfield
country: United States
facility: Gemini Clinical Trial Site
state: Missouri
city: Saint Louis
country: United States
facility: Gemini Clinical Trial Site
state: Missouri
city: Reno
country: United States
facility: Gemini Clinical Trial Site
state: Nevada
city: Bloomfield
country: United States
facility: Gemini Clinical Trial Site
state: New Jersey
city: Asheville
country: United States
facility: Gemini Clinical Trial Site
state: North Carolina
city: Charlotte
country: United States
facility: Gemini Clinical Trial Site
state: North Carolina
city: Eugene
country: United States
facility: Gemini Clinical Trial Site
state: Oregon
city: Rapid City
country: United States
facility: Gemini Clinical Trial Site
state: South Dakota
city: Abilene
country: United States
facility: Gemini Clinical Trial Site
state: Texas
city: Dallas
country: United States
facility: Gemini Clinical Trial Site
state: Texas
city: The Woodlands
country: United States
facility: Gemini Clinical Trial Site
state: Texas
city: Virginia Beach
country: United States
facility: Gemini Clinical Trial Site
state: Virginia
Study officials:
References: